• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Doctors
    • Information
      • Service invoicing
      • Service invoicing for pathologists
    • Clinical trials
      • Lung Cancer Study Group
      • General information
  • Patients
    • General information
      • Driver mutations in lung cancer
      • New immunotherapeutic therapeutic approaches
      • Second Opinion service
      • Molecular Diagnostics
      • New therapeutic approaches from genomic research
    • Clinical trials
      • Lung Cancer Study Group
      • General information
      • What is a clinical trial?
      • Participation in a trial
    • Find doctors nearby
  • The Network
    • Aims
    • Funding
    • Our team
    • Publications
    • Related links
  • Driver mutations
  • Diagnostics
  • Hybrid-capture
  • Fast-track analysis for first-line treatment
Select Page

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

 

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J

Journal: Annals of oncology
published: 2018 Jun 1

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress